Key result
ImaLife study protocol leverages low-dose CT to map early biomarkers of CAD, COPD, and cancer.
Cohort (n=12,000)
Answers are grounded in this paper and cite their sources.
Lung cancer, chronic obstructive pulmonary disease (COPD), and coronary artery disease (CAD) are expected to cause most deaths by 2050. State-of-the-art computed tomography (CT) allows early detection of lung cancer and simultaneous evaluation of imaging biomarkers for the early stages of COPD, based on pulmonary density and bronchial wall thickness, and of CAD, based on the coronary artery calcium score (CACS), at low radiation dose. To determine cut-off values for positive tests for elevated risk and presence of disease is one of the major tasks before considering implementation of CT screening in a general population. The ImaLife (Imaging in Lifelines) study, embedded in the Lifelines study, is designed to establish the reference values of the imaging biomarkers for the big three diseases in a well-defined general population aged 45 years and older. In total, 12,000 participants will undergo CACS and chest acquisitions with latest CT technology. The estimated percentage of individuals with lung nodules needing further workup is around 1-2%. Given the around 10% prevalence of COPD and CAD in the general population, the expected number of COPD and CAD is around 1000 each. So far, nearly 4000 participants have been included. The ImaLife study will allow differentiation between normal aging of the pulmonary and cardiovascular system and early stages of the big three diseases based on low-dose CT imaging. This information can be finally integrated into personalized precision health strategies in the general population.
No takes yet. Share an insight, caveat, or question.
Xia et al. (2019) conducted a cohort in Lung cancer, chronic obstructive pulmonary disease (COPD), and coronary artery disease (CAD) (n=12,000). Low-dose computed tomography (CT) imaging was evaluated on Establish reference values of imaging biomarkers for early stages of lung cancer, COPD, and CAD. The ImaLife cohort study will evaluate low-dose CT imaging in 12,000 adults aged ≥45 to establish reference values for early biomarkers of lung cancer, COPD, and coronary artery disease.
Synapse has enriched 10 related papers. Consider them for comparative context: